Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Accounts Payables (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Accounts Payables readings, the most recent being $28.6 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 121.13% to $28.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.6 million, a 121.13% increase, with the full-year FY2025 number at $28.6 million, up 121.13% from a year prior.
  • Accounts Payables hit $28.6 million in Q4 2025 for Amicus Therapeutics, up from $19.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $32.1 million in Q2 2024 to a low of $9.2 million in Q1 2024.
  • Median Accounts Payables over the past 5 years was $15.8 million (2021), compared with a mean of $18.5 million.
  • The widest YoY moves for Accounts Payables: up 137.07% in 2024, down 63.11% in 2024.
  • Amicus Therapeutics' Accounts Payables stood at $21.5 million in 2021, then decreased by 28.35% to $15.4 million in 2022, then fell by 1.9% to $15.1 million in 2023, then decreased by 14.37% to $12.9 million in 2024, then soared by 121.13% to $28.6 million in 2025.
  • The last three reported values for Accounts Payables were $28.6 million (Q4 2025), $19.1 million (Q3 2025), and $13.9 million (Q2 2025) per Business Quant data.